BamSEC and AlphaSense Join Forces
Learn More

Mangoceuticals Inc.

NASDAQ: MGRX    
Share price (11/22/24): $2.65    
Market cap (11/22/24): $6.589 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 8 pages Consulting Agreement
12/34/56
EX-10.1
from 8-K 10 pages Promissory Note
12/34/56
EX-10.1
from 8-K 11 pages Master Distribution Agreement
12/34/56
EX-10.2
from 8-K 6 pages Omnibus Amendment Agreement No. 1
12/34/56
EX-10.1
from 8-K 21 pages Patent Purchase Agreement
12/34/56
EX-10.4
from 8-K 21 pages Registration Rights Agreement
12/34/56
EX-10.3
from 8-K 21 pages Registration Rights Agreement
12/34/56
EX-10.2
from 8-K 35 pages Equity Purchase Agreement
12/34/56
EX-10.1
from 8-K 31 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 34 pages Mangoceuticals, Inc. Amended and Restated 2022 Equity Incentive Plan Originally Adopted by the Board of Directors On: August 31, 2022 Approved and Ratified by the Stockholders On: August 31, 2022 Amended by the Board of Directors on February 26, 2024 and the Stockholders on March 25, 2024
12/34/56
EX-10.1
from 8-K ~1 page First Amendment to Mangoceuticals, Inc. 2022 Equity Incentive Plan
12/34/56
EX-10.2
from 8-K 12 pages Mangoceuticals, Inc. 2022 Equity Incentive Plan Stock Option Agreement
12/34/56
EX-10.44
from S-1 11 pages Mangoceuticals, Inc. 2022 Equity Incentive Plan Notice of Restricted Stock Grant
12/34/56
EX-10.43
from S-1 5 pages Advisor Agreement
12/34/56
EX-10.1
from 8-K 12 pages Marketing Agreement
12/34/56
EX-10.44
from DRS 11 pages Mangoceuticals, Inc. 2022 Equity Incentive Plan Notice of Restricted Stock Grant
12/34/56
EX-10.43
from DRS 5 pages Advisor Agreement
12/34/56
EX-10.42
from 10-Q 7 pages Mangoceuticals, Inc. Policy for the Recovery of Erroneously Awarded Incentive-Based Compensation
12/34/56
EX-10.1
from 8-K 9 pages Consulting Agreement
12/34/56
EX-10.3
from 8-K 8 pages First Addendum to Master Services Agreement
12/34/56